Given the heterogeneity and rarity of inborn errors of immunity (IEIs), management guidelines that deal with primary immunodeficiency as a whole are rare. The most recent general guideline, the ...
Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been dosed in a Phase II, proof ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results